Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Notre Dame Intermédica on Its R$5.0 Billion Equity Offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Notre Dame…
Forty Seven, Inc. $195.6 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $195…
Constellation Pharmaceuticals Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the …
Davis Polk Advises Venus Medtech (Hangzhou) Inc. on Its HK$2.59 Billion (US$331.17 Million) Initial Public Offering
Davis Polk advised Venus Medtech (Hangzhou) Inc. in connection with its initial public offering and listing on the Hong Kong…
IVERIC bio, Inc. Common Stock and Pre-Funded Warrants Offering
Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $45…
Ardelyx, Inc. $144 Million Follow-On Public Offering
Davis Polk advised the joint book-running managers for the public offering of common stock by Ardelyx, Inc for gross…
Millendo Therapeutics, Inc. $25 Million Offering of Common Shares
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
Kodiak Sciences Inc. $317 Million Follow-On Offering
Davis Polk advised the joint bookrunning managers and representatives of the several underwriters in connection with a $317…
Revance Therapeutics, Inc. $110 Million Common Stock Offering
Davis Polk advised the joint lead book-running managers and representatives of the several underwriters in connection…
AbbVie Inc. $30 Billion Senior Notes Offering
Davis Polk advised the initial purchasers in connection with an unregistered offering by AbbVie Inc. of $30 billion…